Is Secukinumab on the market?

After receiving its first global approval in Japan in December 2014, Secukinumab was approved by the European Commission in January 2015 and a few days later The U.S. Food and Drug Administration (FDA) approved marketing, which is marketed under the brand name Cosentyx, for the treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and other joint inflammatory diseases. It binds to the interleukin (IL)-17A protein.

Interleukin-17 (IL-17) is a family of pro-inflammatory cytokines that mediates normal inflammation and immune responses. IL-17 production is primarily promoted by T cells, such as T helper 17 (Th17) cells, but may also be caused by mast cells and neutrophils. IL-17 binds to IL-17 receptors, which are expressed on various cell types, including keratinocytes. The IL-17 signaling pathway promotes angiogenesis and the release of pro-inflammatory cytokines, chemokines, and tissue damage mediators.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.